2024-05-14 16:05 | UU:FLGT | | News Release200 | Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics |
2024-05-03 07:00 | UU:FLGT | | News Release200 | Fulgent Reports First Quarter 2024 Financial Results |
2024-04-11 16:05 | UU:FLGT | | News Release200 | Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024 |
2024-02-28 07:00 | UU:FLGT | | News Release200 | Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results |
2024-02-13 08:00 | UU:FLGT | | News Release200 | Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024 |
2024-02-09 08:31 | UU:FLGT | | News Release200 | Cord Blood Registry ‚ ® (CBR ‚ ®) by CooperSurgical ‚ ® and Fulgent Genetics Launch Innovative Genetic Testing |
2023-11-14 16:30 | UU:FLGT | | News Release200 | Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference |
2023-11-03 16:05 | UU:FLGT | | News Release200 | Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting |
2023-11-03 07:00 | UU:FLGT | | News Release200 | Fulgent Reports Third Quarter 2023 Financial Results |
2023-10-25 08:00 | UU:FLGT | | News Release200 | Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting |
2023-10-17 08:00 | UU:FLGT | | News Release200 | Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023 |
2023-08-04 07:00 | UU:FLGT | | News Release200 | Fulgent Reports Second Quarter 2023 Financial Results |
2023-07-24 16:05 | UU:FLGT | | News Release200 | Exagen Inc. Appoints Paul Kim to Board of Directors |
2023-07-18 08:00 | UU:FLGT | | News Release200 | Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023 |
2023-06-05 08:30 | UU:FLGT | | News Release200 | Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers |
2023-05-18 16:05 | UU:FLGT | | News Release200 | Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting |